Pearl Steinzor

FIBRONEER Trials Show Nerdanomilast’s Promise as New Treatment Option for IPF/PPF: Toby Maher, MD, PhD

Nerdandomilast has the potential to become a critical new treatment option for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), offering hope where previous clinical trials have failed, says Toby Maher, MD, PhD, professor of clinical medicine,

FIBRONEER Trials Show Nerdanomilast’s Promise as New Treatment Option for IPF/PPF: Toby Maher, MD, PhD Read More »

M. Bradley Drummond, MD, MHS

Ensifentrine showed improved lung function, reduced exacerbations, and better patient-reported outcomes of breathing and overall chronic obstructive pulmonary disease (COPD) management, says M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill. The findings were

M. Bradley Drummond, MD, MHS Read More »